<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hematopoietic stem cell transplantation (HSCT) from a matched unrelated donor (MUD) has become the accepted salvage treatment for patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) lacking a matched sibling donor and failing immunosuppressive treatment </plain></SENT>
<SENT sid="1" pm="."><plain>However, non-engraftment and early rejection remain main reasons for treatment related morbidity and mortality </plain></SENT>
<SENT sid="2" pm="."><plain>We report on three adolescents who were grafted from MUD, rejected their graft and were re-grafted 47-51 days after first HSCT from the same donor </plain></SENT>
<SENT sid="3" pm="."><plain>For conditioning, fludarabine, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, ATG and/or OKT3 in combination with total lymphoid irradiation was used </plain></SENT>
<SENT sid="4" pm="."><plain>Unmanipulated peripheral blood stem cells at a minimum dose of 8 x 10(6)/kg CD34+cells were infused </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> toxicity was low </plain></SENT>
<SENT sid="6" pm="."><plain>Two patients are alive and well for more than 3 years, one patient developed extended <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> from which he died 34 months after second HSCT </plain></SENT>
<SENT sid="7" pm="."><plain>Re-transplantation from MUD in the case of non-engraftment or rejection from the same donor is possible following immunoablation combined with intensive serotherapy in young patients with SAA </plain></SENT>
</text></document>